How CGM Use in Adults With Type 2 Diabetes Leads to Glycemic Benefits: The Role of Medication and Behaviour Change

William H Polonsky 1Taylor L Clark 1Emily C Soriano 2Andrew Edgington 3Cameron M Bennett 4Amy E Fox 4Thomas Grace 5

Abstract

Introduction: Although continuous glucose monitoring (CGM) in adults with type 2 diabetes (T2D) has known glycemic benefits, the underlying behavioural and psychosocial processes driving these outcomes remain poorly understood. We examined how CGM influences patient-reported outcomes and whether changes in those outcomes predict glycemic improvement.

Research design and methods: This 6-month prospective observational study included 115 adults with T2D and elevated HbA1c who did not use fast-acting insulin and initiated CGM through a real-world program. At baseline, 3- and 6-months, HbA1c, medication use/changes and key psychosocial and self-care behaviours were assessed. Longitudinal structural equation models assessed changes over time and predictors of HbA1c reduction. Post hoc moderation analyses explored whether the effect of self-care behaviour improvements on HbA1c outcomes depended upon new medication starts at baseline.

Results: HbA1c declined significantly from 9.4% (79 mmol/mol) at baseline to 7.3% (56 mmol/mol) at both 3 and 6 months (ps < 0.001). Participants reported increased diabetes engagement, reduced distress, increased physical activity, fewer missed medications and less overeating (ps < 0.001). In multivariate models, greater HbA1c reduction was independently predicted by: (1) starting a new diabetes medication in the few months before baseline (b = -1.06, p < 0.001); (2) increases in physical activity (b = -0.13, p = 0.040); and (3) improvements in medication-taking (b = 2.33, p < 0.001). Post hoc moderation analysis revealed that behaviour changes were most predictive of glycemic benefit among participants who had not started a new diabetes medication pre-baseline.

Conclusions: Real-world CGM initiation was associated with significant improvements in glycemic control, self-care behaviours and psychosocial outcomes. Behaviour change-notably, improved diet and physical activity-was a key contributor to glycemic gains, particularly among those not undergoing medication adjustments prior to CGM initiation. These findings support CGM as a catalyst for engagement and behaviour change in T2D management.

How CGM Use in Adults With Type 2 Diabetes Leads to Glycemic Benefits: The Role of Medication and Behaviour Change – PubMed

Share the Post:

BDI Monthly Events

September 9
September 9Case Consultation
September 9: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at info@behavioraldiabetes.org if you are in the greater San Diego area and would like further information about this program.
October 16
October 16Diabetes Data Workshop
BDI friends and fellow healthcare professionals, Adam Brown and Aimeé José, present an in-person half-day workshop for people with diabetes here in San Diego, How to Make Diabetes Data Your Friend. Don’t miss it!
October 24
October 24CME Workshop
On October 24, BDI will host a live, one-day, CME workshop: Engaging the Disengaged: Innovative Strategies for Promoting Behavior Change in Diabetes. Run by Dr. Polonsky (BDI President) and Dr. Guzman (BDI Clinic Director), Participants will deepen their skills in recognizing and addressing common barriers to effective self-care and cardiometabolic medication initiation and maintenance, while fostering respectful, stigma-free clinical encounters.